Latest revenue
$32.8M
as of 2021-09-30
Latest net income
$4.1M
as of 2021-09-30
Net margin
12.4%
as of 2021-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AVIR is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for AVIR.
5-year trend
What this company does
Item 1. Business. Overview We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care (“SOC”) for the treatment of patients with hepatitis C virus (“HCV”) infection and AT-587 which we believe has the potential to be the first direct-acting antiviral (“DAA”) for the treatment of patients, particularly…
AI summary unavailable — showing raw filing excerpt
Generated from AVIR's filing dated 2026-03-05
Key risks
Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Results of Operations and Financial Condition.” Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. Our actual results could differ materially and adversely from those anticipated in these forward-looking…
AI summary unavailable — showing raw filing excerpt
Generated from AVIR's filing dated 2026-03-05
Profitability
Operating margin
39.4%
Net margin
34.5%
Return on equity
-57.5%
49.8%Return on assets
-50.2%
38.6%Leverage
Debt / equity
0.14×
145.7%Debt / assets
12.6%
127.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-45.4M | -32.6% | — |
Q4 2025 2025-12-31 | — | — | $-44.9M | -33.8% | — |
Q3 2025 2025-09-30 | — | — | $-42.0M | -35.0% | — |
Q2 2025 2025-06-30 | — | — | $-37.2M | +8.3% | — |
Q1 2025 2025-03-31 | — | — | $-34.3M | +45.7% | — |
Q4 2024 2024-12-31 | — | — | $-33.5M | — | — |
Q3 2024 2024-09-30 | — | — | $-31.2M | +6.0% | — |
Q2 2024 2024-06-30 | — | — | $-40.5M | -43.8% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AVIR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$25.4K
Insider selling
$0
Net activity
+$25.4K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVIR
Institutional value
$138.0M
Total shares held
27.3M
Distinct holders
66
-45 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.4M | $45.4M | -55.8K (-0.7%) | Trimmed |
| 2 | BML Capital Management, LLC | 7.1M | $38.0M | -431.3K (-5.8%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $17.5M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.3M | $6.8M | -118.5K (-8.6%) | Trimmed |
| 5 | JPMORGAN CHASE & CO | 940.2K | $4.8M | -408.1K (-30.3%) | Trimmed |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 557.6K | $3.0M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 484.7K | $2.6M | — | New |
| 8 | JANE STREET GROUP, LLC | 418.3K | $2.3M | +167.6K (+66.8%) | Added |
| 9 | CM Management, LLC | 355.0K | $1.9M | +0 (+0.0%) | No change |
| 10 | BANQUE PICTET & CIE SA | 345.1K | $1.9M | +0 (+0.0%) | No change |
| 11 | Peapod Lane Capital LLC | 272.8K | $1.4M | -162.2K (-37.3%) | Trimmed |
| 12 | HSBC HOLDINGS PLC | 259.0K | $1.4M | -223.6K (-46.3%) | Trimmed |
| 13 | Nuveen, LLC | 243.1K | $1.3M | +2.5K (+1.0%) | Added |
| 14 | Bank of New York Mellon Corp | 185.8K | $999.6K | -12.7K (-6.4%) | Trimmed |
| 15 | Auour Investments LLC | 177.0K | $952.3K | +0 (+0.0%) | No change |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 156.4K | $841.4K | +132.3K (+548.0%) | Added |
| 17 | SEI INVESTMENTS CO | 156.4K | $841.3K | — | New |
| 18 | Invesco Ltd. | 133.3K | $717.4K | +45.4K (+51.7%) | Added |
| 19 | EAM Investors, LLC | 112.9K | $607.2K | — | New |
| 20 | UBS Group AG | 110.0K | $591.5K | -82.6K (-42.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVIR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.